AAAAAA
Results:
1-17
|
Results: 17
Authors:
Abernethy, DR
Wesche, DL
Barbey, JT
Ohrt, C
Mohanty, S
Pezzullo, JC
Schuster, BG
Citation: Dr. Abernethy et al., Stereoselective halofantrine disposition and effect: concentration-relatedQTc prolongation, BR J CL PH, 51(3), 2001, pp. 231-237
Authors:
Abernethy, DR
Barbey, JT
Franc, J
Brown, KS
Feirrera, I
Ford, N
Salazar, DE
Citation: Dr. Abernethy et al., Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation, CLIN PHARM, 69(3), 2001, pp. 96-103
Authors:
Andrawis, NS
Battle, MM
Klamerus, KJ
Burghart, PH
Neefe, L
Weinryb, I
Mayer, P
Abernethy, DR
Citation: Ns. Andrawis et al., A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension, J CLIN PHAR, 40(3), 2000, pp. 231-241
Authors:
Abernethy, DR
Wainer, IW
Anacleto, AI
Citation: Dr. Abernethy et al., Verapamil metabolite exposure in older and younger men during steady-stateoral verapamil administration, DRUG META D, 28(7), 2000, pp. 760-765
Authors:
Soldatov, NM
Zhenochin, S
AlBanna, B
Abernethy, DR
Morad, M
Citation: Nm. Soldatov et al., New molecular determinant for inactivation of the human L-type alpha(1C) Ca2+ channel, J MEMBR BIO, 177(2), 2000, pp. 129-135
Authors:
Romanin, C
Gamsjaeger, R
Kahr, H
Schaufler, D
Carlson, O
Abernethy, DR
Soldatov, NM
Citation: C. Romanin et al., Ca2+ sensors of L-type Ca2+ channel, FEBS LETTER, 487(2), 2000, pp. 301-306
Authors:
Spyker, DA
Harvey, ED
Harvey, BE
Harvey, AM
Rumack, BH
Peck, CC
Atkinson, AJ
Woosley, RL
Abernethy, DR
Cantilena, LR
Citation: Da. Spyker et al., Assessment and reporting of clinical pharmacology information in drug labeling - Commentary, CLIN PHARM, 67(3), 2000, pp. 196-200
Authors:
Abernethy, DR
Flockhart, DA
Citation: Dr. Abernethy et Da. Flockhart, Molecular basis of cardiovascular drug metabolism - Implications for predicting clinically important drug interactions, CIRCULATION, 101(14), 2000, pp. 1749-1753
Authors:
Andrawis, N
Jones, DS
Abernethy, DR
Citation: N. Andrawis et al., Aging is associated with endothelial dysfunction in the human forearm vasculature, J AM GER SO, 48(2), 2000, pp. 193-198
Authors:
Kimko, HC
Cross, JT
Abernethy, DR
Citation: Hc. Kimko et al., Pharmacokinetics and clinical effectiveness of methylphenidate, CLIN PHARMA, 37(6), 1999, pp. 457-470
Authors:
Abernethy, DR
Schwartz, JB
Citation: Dr. Abernethy et Jb. Schwartz, Calcium-antagonist drugs, N ENG J MED, 341(19), 1999, pp. 1447-1457
Authors:
Donahue, S
Flockhart, DA
Abernethy, DR
Citation: S. Donahue et al., Ticlopidine inhibits phenytoin clearance, CLIN PHARM, 66(6), 1999, pp. 563-568
Authors:
Schulman, KA
Abernethy, DR
Rathore, SS
Woosley, RL
Citation: Ka. Schulman et al., Regulating manufacturer-affiliated communication in the information age, CLIN PHARM, 65(6), 1999, pp. 593-597
Authors:
Jones, DS
Andrawis, NS
Abernethy, DR
Citation: Ds. Jones et al., Impaired endothelial-dependent forearm vascular relaxation in black Americans, CLIN PHARM, 65(4), 1999, pp. 408-412
Authors:
Rodriguez, I
Abernethy, DR
Woosley, RL
Citation: I. Rodriguez et al., P-glycoprotein in clinical cardiology, CIRCULATION, 99(4), 1999, pp. 472-474
Authors:
Oz, M
Melia, MT
Soldatov, NM
Abernethy, DR
Morad, M
Citation: M. Oz et al., Functional coupling of human L-type Ca2+ channels and angiotensin AT(1A) receptors coexpressed in Xenopus laevis oocytes: Involvement of the carboxyl-terminal Ca2+ sensors, MOLEC PHARM, 54(6), 1998, pp. 1106-1112
Authors:
Trapnell, CB
Donahue, SR
Collins, JM
Flockhart, DA
Thacker, D
Abernethy, DR
Citation: Cb. Trapnell et al., Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone, CLIN PHARM, 64(6), 1998, pp. 597-602
Risultati:
1-17
|